JP2013519636A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013519636A5 JP2013519636A5 JP2012552352A JP2012552352A JP2013519636A5 JP 2013519636 A5 JP2013519636 A5 JP 2013519636A5 JP 2012552352 A JP2012552352 A JP 2012552352A JP 2012552352 A JP2012552352 A JP 2012552352A JP 2013519636 A5 JP2013519636 A5 JP 2013519636A5
- Authority
- JP
- Japan
- Prior art keywords
- fviii
- domain
- linked
- psa
- fviii variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100000368 F8 Human genes 0.000 claims 18
- 101700070229 F8 Proteins 0.000 claims 18
- 229920000642 polymer Polymers 0.000 claims 12
- 229920001542 oligosaccharide Polymers 0.000 claims 7
- 150000002482 oligosaccharides Polymers 0.000 claims 7
- 229920001223 polyethylene glycol Polymers 0.000 claims 5
- 150000004676 glycans Polymers 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 229920001282 polysaccharide Polymers 0.000 claims 3
- 239000005017 polysaccharide Substances 0.000 claims 3
- 150000004804 polysaccharides Polymers 0.000 claims 3
- 230000004913 activation Effects 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000001268 conjugating Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000003542 factor VIII deficiency Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Claims (16)
- 少なくとも1つのPEG重合体および少なくとも1つの多糖とコンジュゲートしたFVIIIバリアント。
- 前記多糖がPSAである、請求項1に記載のFVIIIバリアント。
- 末端欠失型Bドメイン内のO連結オリゴ糖を介してPEG重合体またはPSA重合体と共有結合によってコンジュゲートしたBドメイン末端欠失型FVIII分子であり、FVIII活性化が前記O連結重合体の除去をもたらす、請求項1〜2のいずれか一項に記載のFVIIIバリアント。
- 末端欠失型Bドメイン内のO連結オリゴ糖を介してPEG重合体と共有結合によってコンジュゲートしており、N連結オリゴ糖を介して少なくとも1つのPSA重合体と共有結合によってコンジュゲートしている、請求項1〜3のいずれか一項に記載のFVIIIバリアント。
- A1ドメイン内の1つの二重分枝N連結オリゴ糖およびA3ドメイン内の1つの二重分枝N連結オリゴ糖に連結された2〜4つのPSA重合体を含む、請求項4に記載のFVIIIバリアント。
- A1ドメイン内の1つの二重分枝N連結オリゴ糖に連結された1つまたは2つのPSA重合体を含む、請求項4に記載のFVIIIバリアント。
- A3ドメイン内の1つの二重分枝N連結オリゴ糖に連結された1つまたは2つのPSA重合体を含む、請求項4に記載のFVIIIバリアント。
- 前記PEG重合体のサイズが30〜50kDaである、請求項1〜7のいずれか一項に記載のFVIIIバリアント。
- PSA重合体のサイズが40〜50kDaである、請求項1〜8のいずれか一項に記載のFVIIIバリアント。
- Bドメイン末端欠失型FVIIIバリアントであり、Bドメインが配列番号2に記載のアミノ酸配列を含む、請求項1〜9のいずれか一項に記載のFVIIIバリアント。
- 請求項1〜10のいずれか一項に記載のFVIIIバリアントを作製する方法であって、FVIII分子を少なくとも1つのPEG重合体および少なくとも1つの多糖とコンジュゲートする工程を含む方法。
- 請求項11に記載の方法によって取得されたFVIIIバリアント。
- 請求項1〜10または12のいずれか一項に記載のFVIIIバリアントを含む医薬組成物。
- 1つまたは複数の薬学的に許容できる添加剤をさらに含む、請求項13に記載の医薬組成物。
- 請求項1〜10のいずれか一項もしくは請求項12に記載のFVIIIバリアントまたは請求項13もしくは14に記載の医薬組成物を含む医薬。
- 血友病Aを治療するための、請求項15に記載の医薬。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10153718.1 | 2010-02-16 | ||
| EP10153718 | 2010-02-16 | ||
| US30560810P | 2010-02-18 | 2010-02-18 | |
| US61/305,608 | 2010-02-18 | ||
| PCT/EP2011/051723 WO2011101267A1 (en) | 2010-02-16 | 2011-02-07 | Conjugated fviii variants |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013519636A JP2013519636A (ja) | 2013-05-30 |
| JP2013519636A5 true JP2013519636A5 (ja) | 2014-03-27 |
| JP5933457B2 JP5933457B2 (ja) | 2016-06-08 |
Family
ID=42173354
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012553254A Expired - Fee Related JP5914363B2 (ja) | 2010-02-16 | 2011-02-02 | 低減されたｖｗｆ結合を有する因子ｖｉｉｉ分子 |
| JP2012552352A Expired - Fee Related JP5933457B2 (ja) | 2010-02-16 | 2011-02-07 | コンジュゲートｆｖｉｉｉバリアント |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012553254A Expired - Fee Related JP5914363B2 (ja) | 2010-02-16 | 2011-02-02 | 低減されたｖｗｆ結合を有する因子ｖｉｉｉ分子 |
Country Status (5)
| Country | Link |
|---|---|
| US (4) | US20130040888A1 (ja) |
| EP (2) | EP2536753B1 (ja) |
| JP (2) | JP5914363B2 (ja) |
| CN (3) | CN105524164A (ja) |
| WO (2) | WO2011101242A1 (ja) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6263355A (ja) * | 1985-09-13 | 1987-03-20 | Hitachi Ltd | バツテリバツクアツプｒａｍのチエツク方法 |
| CN103804489A (zh) | 2006-12-15 | 2014-05-21 | 巴克斯特国际公司 | 具有延长的体内半衰期的因子VIIa-聚唾液酸结合物 |
| ES2551123T3 (es) | 2007-06-12 | 2015-11-16 | Ratiopharm Gmbh | Proceso mejorado para la producción de azúcares de nucleótido |
| WO2010091122A1 (en) | 2009-02-03 | 2010-08-12 | Amunix, Inc. | Extended recombinant polypeptides and compositions comprising same |
| TWI537006B (zh) | 2009-07-27 | 2016-06-11 | 巴克斯歐塔公司 | 凝血蛋白接合物 |
| NZ597600A (en) | 2009-07-27 | 2014-05-30 | Lipoxen Technologies Ltd | Glycopolysialylation of non-blood coagulation proteins |
| US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| RU2744370C2 (ru) | 2009-07-27 | 2021-03-05 | Баксалта Инкорпорейтед | Конъюгаты белков свертывания крови |
| US20120263701A1 (en) | 2009-08-24 | 2012-10-18 | Volker Schellenberger | Coagulation factor vii compositions and methods of making and using same |
| WO2011075185A1 (en) | 2009-12-18 | 2011-06-23 | Oligasis | Targeted drug phosphorylcholine polymer conjugates |
| GB201007356D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
| CA2822591C (en) | 2010-12-22 | 2020-12-29 | Baxter International Inc. | Materials and methods for conjugating a water soluble fatty acid derivative to a protein |
| WO2013106787A1 (en) * | 2012-01-12 | 2013-07-18 | Biogen Idec Ma Inc. | Chimeric factor viii polypeptides and uses thereof |
| AU2013204636B2 (en) | 2012-02-15 | 2016-04-14 | Bioverativ Therapeutics Inc. | Recombinant Factor VIII proteins |
| PL3564260T3 (pl) | 2012-02-15 | 2023-03-06 | Bioverativ Therapeutics Inc. | Kompozycje czynnika viii oraz sposoby ich wytwarzania i stosowania |
| MD20140123A2 (ro) * | 2012-04-16 | 2015-04-30 | Cantab Biopharmaceuticals Patents Limited | Agenţi terapeutici optimizaţi pentru administrare subcutanată |
| PL2882450T3 (pl) * | 2012-07-11 | 2020-06-29 | Bioverativ Therapeutics Inc. | Kompleks czynnika viii z xten i białkiem czynnika von willebranda oraz jego zastosowania |
| JP2015533152A (ja) | 2012-10-15 | 2015-11-19 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 第ｖｉｉ因子コンジュゲート |
| EP2796145B1 (en) * | 2013-04-22 | 2017-11-01 | CSL Ltd. | A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge |
| TW202003554A (zh) * | 2013-08-14 | 2020-01-16 | 美商百歐維拉提夫治療公司 | 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途 |
| EP3041513B1 (en) | 2013-09-08 | 2020-08-05 | Kodiak Sciences Inc. | Factor viii zwitterionic polymer conjugates |
| BR112016008039A2 (pt) | 2013-10-15 | 2017-10-17 | Novo Nordisk Healthcare Ag | polipeptídeos do fator vii da coagulação |
| IL282168B2 (en) | 2014-01-10 | 2023-03-01 | Bioverativ Therapeutics Inc | Factor viii chimeric proteins and their uses |
| AR101060A1 (es) * | 2014-02-12 | 2016-11-23 | Novo Nordisk As | Conjugados de fviii |
| AR099340A1 (es) * | 2014-02-12 | 2016-07-13 | Novo Nordisk As | Conjugados del factor de coagulación ix |
| AR099328A1 (es) * | 2014-02-12 | 2016-07-13 | Novo Nordisk As | Conjugados de factor vii |
| MX2016012428A (es) * | 2014-03-23 | 2017-04-27 | Advantech Bioscience Farmacêutica Ltda | Aumento de la expresion de proteina recombinante con cobre. |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| ES2788870T3 (es) | 2014-08-04 | 2020-10-23 | Csl Ltd | Formulación de factor VIII |
| EP3207128B1 (en) | 2014-10-17 | 2022-07-27 | Kodiak Sciences Inc. | Butyrylcholinesterase zwitterionic polymer conjugates |
| EP3042952A1 (en) * | 2015-01-07 | 2016-07-13 | CEVEC Pharmaceuticals GmbH | O-glycan sialylated recombinant glycoproteins and cell lines for producing the same |
| US11155601B2 (en) | 2015-03-06 | 2021-10-26 | CSL Behring Lengnau AG | Modified von Willebrand factor having improved half-life |
| CN108472337B (zh) | 2015-08-03 | 2022-11-25 | 比奥贝拉蒂治疗公司 | 因子ix融合蛋白以及其制备和使用方法 |
| SG11201805420SA (en) * | 2015-12-30 | 2018-07-30 | Kodiak Sciences Inc | Antibodies and conjugates thereof |
| WO2017222337A1 (ko) | 2016-06-24 | 2017-12-28 | 재단법인 목암생명과학연구소 | Fviii 및 vwf 인자를 포함하는 키메라 단백질 및 그 용도 |
| EP3476860A4 (en) * | 2016-06-24 | 2020-01-22 | Mogam Institute for Biomedical Research | RECOMBINANT SINGLE CHAIN FVIII AND CHEMICAL CONJUGATE THEREOF |
| EP3382014A1 (en) | 2017-03-29 | 2018-10-03 | CEVEC Pharmaceuticals GmbH | Recombinant glycoproteins with reduced antennary fucosylation |
| CN111183151B (zh) * | 2017-06-23 | 2024-06-07 | 武田药品工业株式会社 | 因子viii亚种的纯化 |
| EP3816181A4 (en) * | 2018-05-18 | 2022-04-20 | Zhengzhou Gensciences Inc. | IMPROVED FVIII FUSION PROTEIN AND ITS USE |
| KR20220029733A (ko) | 2019-07-04 | 2022-03-08 | 체에스엘 베링 렝나우 아게 | 응고 인자 viii의 시험관내 안정성을 증가시키기 위한 절단된 폰 빌레브란트 인자 (vwf) |
| AU2020338947A1 (en) | 2019-08-27 | 2022-03-31 | Tonix Pharma Limited | Modified TFF2 polypeptides |
| CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
| JP2023500953A (ja) | 2019-11-11 | 2023-01-11 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | 第ｖｉｉｉ因子に対する寛容を誘導するためのポリペプチド |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4356170A (en) | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
| AU2645588A (en) | 1987-12-04 | 1989-06-15 | Scripps Clinic And Research Foundation | The von willebrand factor binding domain of factor viii |
| US5629384A (en) | 1994-05-17 | 1997-05-13 | Consiglio Nazionale Delle Ricerche | Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| DE4437544A1 (de) * | 1994-10-20 | 1996-04-25 | Behringwerke Ag | Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| JP4574007B2 (ja) | 1998-04-28 | 2010-11-04 | メルク・セローノ・ソシエテ・アノニム | ポリオール−ｉｆｎ−ベータ複体 |
| US6759216B1 (en) * | 1998-11-06 | 2004-07-06 | Emory University | Glycosylated, low antigenicity low immunogenicity factor VIII |
| EP2292271A3 (en) | 2001-10-10 | 2011-09-14 | BioGeneriX AG | Remodelling and glycoconjugation of an antibody |
| US7157277B2 (en) * | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
| JP4758608B2 (ja) * | 2001-11-07 | 2011-08-31 | ネクター セラピューティックス | 分枝ポリマーおよびそれらの結合体 |
| WO2003062290A1 (en) | 2002-01-16 | 2003-07-31 | Biocompatibles Uk Limited | Polymer conjugates |
| WO2005016974A1 (en) | 2003-08-12 | 2005-02-24 | Lipoxen Technologies Limited | Sialic acid derivatives for protein derivatisation and conjugation |
| EP3153181A1 (en) | 2004-11-12 | 2017-04-12 | Bayer HealthCare LLC | Site-directed modification of fviii bdd |
| CN101160326B (zh) | 2005-02-23 | 2013-04-10 | 利普生技术有限公司 | 用于蛋白质衍生和缀合的活化的唾液酸衍生物 |
| KR20080021590A (ko) | 2005-03-24 | 2008-03-07 | 네오스 테크놀로지스, 인크. | 가용성이고 활성인 진핵생물 글리코실트랜스퍼라제의원핵생물 유기체 내에서의 발현 |
| WO2006103298A2 (en) * | 2005-04-01 | 2006-10-05 | Novo Nordisk Health Care Ag | Blood coagulation fviii analogues |
| WO2006134148A2 (en) | 2005-06-15 | 2006-12-21 | Novo Nordisk Health Care Ag | Transglutaminase mediated conjugation of growth hormone |
| US20070105755A1 (en) * | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
| WO2007056191A2 (en) | 2005-11-03 | 2007-05-18 | Neose Technologies, Inc. | Nucleotide sugar purification using membranes |
| WO2007087711A1 (en) | 2006-01-31 | 2007-08-09 | National Research Council Of Canada | Production of polysialic acid containing glyconjugates using a self-priming polysialyltransferase |
| KR20080108147A (ko) | 2006-03-31 | 2008-12-11 | 백스터 인터내셔널 인코포레이티드 | 페질화된 인자 ｖｉｉｉ |
| US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
| JP2009544327A (ja) * | 2006-07-21 | 2009-12-17 | ノヴォ ノルディスク アー／エス | Ｏ−結合型グリコシル化配列によるペプチドのグリコシル化 |
| CN103804489A (zh) | 2006-12-15 | 2014-05-21 | 巴克斯特国际公司 | 具有延长的体内半衰期的因子VIIa-聚唾液酸结合物 |
| EP2162535A4 (en) | 2007-06-04 | 2011-02-23 | Novo Nordisk As | O-linked glycosylation using N-acetylglucosamine transferases |
| JP5356373B2 (ja) | 2007-06-15 | 2013-12-04 | ナショナル リサーチ カウンシル オブ カナダ | 酵素特性を向上させたポリシアリルトランスフェラーゼの操作されたバージョン |
| GB2467700A (en) * | 2007-11-09 | 2010-08-11 | Baxter Int | Modified recombinant Factor VIII and von Willebrand Factor and methods of use |
| US20100286067A1 (en) * | 2008-01-08 | 2010-11-11 | Biogenerix Ag | Glycoconjugation of polypeptides using oligosaccharyltransferases |
| CN101965200B (zh) * | 2008-02-27 | 2013-06-19 | 诺沃-诺迪斯克有限公司 | 缀合的因子ⅷ分子 |
| CN103739712B (zh) | 2008-06-24 | 2016-10-05 | 德国杰特贝林生物制品有限公司 | 具有延长的体内半衰期的因子viii、冯·维勒布兰德因子或它们的复合物 |
| PL2349342T3 (pl) | 2008-10-17 | 2019-01-31 | Baxalta GmbH | Zmodyfikowane czynniki krwi zawierające mały stopień polimeru rozpuszczalnego w wodzie |
| CN102333788A (zh) | 2009-02-19 | 2012-01-25 | 诺沃—诺迪斯克有限公司 | 因子viii的修饰 |
| WO2010115866A1 (en) * | 2009-04-06 | 2010-10-14 | Novo Nordisk A/S | Targeted delivery of factor viii proteins to platelets |
| EP2536754A1 (en) * | 2010-02-16 | 2012-12-26 | Novo Nordisk A/S | Factor viii fusion protein |
-
2011
- 2011-02-02 US US13/574,142 patent/US20130040888A1/en not_active Abandoned
- 2011-02-02 CN CN201610048268.1A patent/CN105524164A/zh not_active Withdrawn
- 2011-02-02 JP JP2012553254A patent/JP5914363B2/ja not_active Expired - Fee Related
- 2011-02-02 WO PCT/EP2011/051438 patent/WO2011101242A1/en active Application Filing
- 2011-02-02 CN CN201180009856.XA patent/CN102770449B/zh not_active Expired - Fee Related
- 2011-02-02 EP EP11701527.1A patent/EP2536753B1/en not_active Not-in-force
- 2011-02-07 US US13/577,310 patent/US9018166B2/en not_active Expired - Fee Related
- 2011-02-07 CN CN201180009852.1A patent/CN102884077B/zh not_active Expired - Fee Related
- 2011-02-07 JP JP2012552352A patent/JP5933457B2/ja not_active Expired - Fee Related
- 2011-02-07 EP EP11717973A patent/EP2536755A1/en not_active Withdrawn
- 2011-02-07 WO PCT/EP2011/051723 patent/WO2011101267A1/en active Application Filing
-
2015
- 2015-09-11 US US14/851,395 patent/US20150376262A1/en not_active Abandoned
-
2016
- 2016-10-07 US US15/288,248 patent/US20170020992A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013519636A5 (ja) | ||
| JP2013519697A5 (ja) | ||
| IN2014DN00101A (ja) | ||
| EA201890389A3 (ru) | Композиции конъюгата xten и способы их получения | |
| JP2012255007A5 (ja) | ||
| JP2015536943A5 (ja) | ||
| JP2011515499A5 (ja) | ||
| CR20110515A (es) | Compuesto biocompatible y su uso | |
| EA201170039A1 (ru) | Полимерные частицы, нагруженные лекарственным средством, и способы их получения и применения | |
| JP2015519313A5 (ja) | ||
| JP2012508172A5 (ja) | ||
| WO2013096901A8 (en) | Pharmaceutical formulations for fumagillin derivative-phf conjugates | |
| BR112012012210B8 (pt) | conjugado de (cdp)-taxano de polímero contendo ciclodextrina, composição, composição farmacêutica, forma de dosagem, kit e uso de um conjugado de cdp-taxano | |
| JP2017511322A5 (ja) | ||
| WO2010122385A8 (fr) | Formulation a action rapide d'insuline | |
| GB201105455D0 (en) | Blends of a polylactic acid and a water soluble polymer | |
| WO2011015634A3 (en) | Controlled release formulations of lipocalin muteins | |
| SG194175A1 (en) | Polymer conjugated prostaglandin analogues | |
| UA101497C2 (ru) | Конъюгаты фактора ix с увеличенным временем полужизни | |
| WO2011057225A3 (en) | Self-assembled particles from zwitterionic polymers and related methods | |
| AU2019268096A1 (en) | Pharmaceutical compositions comprising modified fucans for use in the treatment of fibrous adhesions and other disorders | |
| WO2011112482A3 (en) | Polymeric drug delivery conjugates and methods of making and using thereof | |
| JP2014058562A5 (ja) | ||
| WO2011126839A3 (en) | Compositions and methods for improved retention of a pharmaceutical composition at a local administration site | |
| CA2402421A1 (en) | Clathrate complexes formed by hyaluronic acid derivatives and use thereof as pharmaceuticals |